lung cancer
Chapter 27: Cancer of the Lung
Etiology
Leading Cause of Cancer Deaths: Lung cancer is recognized as the leading cause of cancer-related deaths in the United States.
Annual Incidence: More than 228,190 new cases reported annually in the United States, broken down by gender:
Approximately 118,080 cases in males.
Approximately 110,110 cases in females.
Anatomic Alterations of the Lungs
Various anatomic changes associated with lung cancer include:
Inflammation, swelling, and destruction of bronchial airways and alveoli.
Excessive mucus production leading to tracheobronchial mucus accumulation and airway obstruction.
Tumors can project into a bronchus causing blockage.
Potential consequences include:
Atelectasis (collapse of lung tissue).
Alveolar consolidation (fluid in the alveoli).
Cavity formation in lung tissues.
Pleural effusion (fluid accumulation in the pleural space).
Types of Cancer
Non-Small-Cell Lung Cancer (NSCLC): Composed of:
Squamous cell carcinoma.
Adenocarcinoma.
Large-cell carcinoma (Undifferentiated).
Small-Cell Lung Cancer (SCLC): Also known as small-cell or oat cell carcinoma.
Characteristics of Lung Cancers
Table 26-1 summarizes the characteristics of lung cancers:
Squamous Cell Carcinoma:
Growth Rate: Slow
Metastasis: Late; primarily to hilar lymph nodes
Means of Diagnosis: Biopsy, sputum analysis, bronchoscopy, and electron microscopy.
Adenocarcinoma:
Growth Rate: Moderate
Metastasis: Early and widespread
Means of Diagnosis: Radiography, sputum analysis, bronchoscopy, and electron microscopy.
Large-Cell Carcinoma:
Growth Rate: Rapid
Metastasis: Early
Means of Diagnosis: Similar to adenocarcinoma.
Small-Cell (Oat Cell) Carcinoma:
Growth Rate: Very rapid
Metastasis: Very early; can spread to the mediastinum or distally in the lung.
Screening and Diagnosis
Common Screening Methods include:
Routine chest x-ray.
Computed tomography (CT) scan.
Positron emission tomography (PET) scan.
Tissue biopsy is definitive for diagnosis.
Procedures for Tissue Biopsy
Various procedures for obtaining tissue biopsy include:
Bronchoscopy.
Thoracoscopy.
Transbronchial needle biopsy.
Open-lung biopsy.
Sputum cytology.
Thoracentesis.
Video thoracoscopy.
Staging of Lung Cancer
Staging Process: Classification based on several factors:
Type of cancer.
Size of the tumor.
Level of lymph node involvement.
Extent of cancer spread.
Important for evaluating prognosis and treatment options.
TNM Classification System
Components of Staging:
T: Extent of the primary tumor.
N: Lymph node involvement.
M: Extent of metastasis.
Use of Roman numerals (I to IV) to designate stages with 0 being the least advanced and IV the most.
Definitions of Staging Symbols
Primary Tumor (T):
T0: No evidence of tumor.
Tx: Tumor that cannot be assessed.
Lymph Nodes (N):
Nx: Regional lymph nodes cannot be assessed.
N0: Absence of regional lymph involvement.
Distant Metastasis (M):
Mx: Metastasis cannot be assessed.
M0: Absence of distant metastasis.
Stage Classifications
Stage I: T1 (with or without nodal involvement).
Stage II: More advanced tumors (T2N1).
Stage III: Includes advanced involvement (T2N2).
Stage IV: Most advanced with distant spread.
Staging of Non-Small-Cell Cancer
Subcategories of Staging:
Stage 0.
Stage I.
Stage II.
Stage III A.
Stage III B.
Stage IV.
Staging of Small-Cell Cancer
Classified into two categories:
Limited: Confined to one lung and neighboring lymph nodes.
Extensive: Spread beyond one lung and neighboring lymph nodes, potentially to both lungs or other organs.
Clinical Manifestations
Common Symptoms:
Atelectasis.
Alveolar consolidation.
Excessive bronchial secretions.
Clinical Data at Patient’s Bedside
Physical Examination Findings:
Vital Signs:
Increased respiratory rate (tachypnea).
Increased heart rate (pulse).
Potential changes in blood pressure.
Cyanosis: Indicating low oxygen saturation.
Cough, Sputum Production, Hemoptysis (coughing blood).
Chest Assessment Findings:
Presence of crackles, rhonchi, wheezing.
Pulmonary Function Testing (PFT)
The results may vary based on tumor origin and may indicate:
Obstructive Values: When malignancy obstructs major airways (especially with COPD).
Restrictive Values: When large areas of lung tissue are affected, for example, in extensive bronchioalveolar carcinoma.
Hemodynamics
Changes that may occur in relation to hypoxemia and acidosis due to tumor interaction with mediastinal structures:
Central Venous Pressure (CVP): Increased.
Pulmonary Artery (PA) Pressure: Decreased.
Pulmonary Capillary Wedge Pressure (PCWP): Normal or decreased.
Cardiac Output (CO): May be decreased or normal.
Chest Radiograph Findings
Potential Indicators:
Small oval or coin-like lesion.
Large irregular masses.
Alveolar consolidation.
Atelectasis.
Pleural effusion.
Mediastinal or diaphragmatic involvement.
Imaging Findings
Figure References:
Illustrations depict various abnormalities including squamous cell carcinoma, suspicious nodules, and confirmed malignant nodules highlighting the importance of diagnostic imaging in lung cancer detection.
Common Non-Respiratory Manifestations
Symptoms Indicating Miscellaneous Issues:
Hoarseness.
Difficulty swallowing.
Superior vena cava syndrome.
General weakness and neck and facial edema.
Electrolyte abnormalities.
General Management of Lung Cancer
Treatment Modalities:
Surgery: Various procedures depending on tumor staging, including:
Wedge resection.
Segmentectomy.
Lobectomy.
Bilobectomy.
Pneumonectomy.
Chemotherapy: Involves chemical agents targeting malignant cells.
Radiation Therapy: Often given palliatively or curatively when surgery is not an option.
Comfort and Supportive Care
In cases of extensive small-cell lung cancer in deteriorating health:
Emphasis on comfort and palliative care rather than aggressive treatment.
Therapist Driven Protocols
Therapeutic approaches include:
Oxygen Therapy Protocol.
Bronchopulmonary Hygiene Therapy Protocol.
Lung Expansion Therapy Protocol.
Aerosolized Medication.